Fan Zhong-Guo, Ji Ming-Yue, Xu Yang, Wang Wan-Xin, Lu Jing, Ma Gen-Shan
Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, 210009 Nanjing, Jiangsu, China.
Department of Cardiology, Lianshui People's Hospital, 223400 Huaian, Jiangsu, China.
Rev Cardiovasc Med. 2023 Apr 23;24(4):123. doi: 10.31083/j.rcm2404123. eCollection 2023 Apr.
Dynamin-related protein 1 (Drp1) has been demonstrated as a crucial role in mediating the programed cell death and cardiac metabolism through its regulatory of mitophagy in animal studies. However, the clinical values of Drp1 for human cardiac disease remain unknown. This study is aimed to evaluate the diagnostic and prognostic values of serum Drp1 in these patients with heart failure (HF).
The enzyme linked immunosorbent assay (ELISA) was used for measuring serum Drp1 concentrations in 85 cases of HF with preserved ejection fraction (HFpEF) and 86 cases of HF with reduced ejection fraction (HFrEF). The diagnostic value of Drp1 was evaluated using the receiver operating characteristic (ROC) analysis. The composite endpoint was consisted of cardiac death and rehospitalization for HF, and the association between Drp1 and clinical outcomes were further determined.
Serum Drp1 concentrations were much higher in HFpEF than that in HFrEF (4.2 3.7 ng/mL vs. 2.6 2.2 ng/mL, = 0.001) and the ROC analysis demonstrated it as a potential diagnostic biomarker for distinction of the HF phenotypes, with an optimal cutoff point of 3.5 ng/mL (area under the curve (AUC) = 0.659, sensitivity: 45.9%, specificity: 83.7%). Kaplan-Meier survival analysis indicated that a low serum concentration of Drp1 (cut-off value = 2.5 ng/mL, AUC = 0.738) was in relation to poor prognosis of HF. Moreover, binary logistic regression analysis identified the low serum concentration of Drp1 as an independent risk predictor for rehospitalization (odds ratio (OR) = 6.574, = 0.001) and a composite endpoint (OR = 5.927, = 0.001).
Our findings suggested that low serum concentrations of Drp1 might serve as a predicting biomarker for distinction of HF phenotypes and overall prognosis of HF.
在动物研究中,动力相关蛋白1(Drp1)已被证明通过调节线粒体自噬在介导程序性细胞死亡和心脏代谢中起关键作用。然而,Drp1在人类心脏病中的临床价值仍不清楚。本研究旨在评估血清Drp1在这些心力衰竭(HF)患者中的诊断和预后价值。
采用酶联免疫吸附测定(ELISA)法测定85例射血分数保留的心力衰竭(HFpEF)患者和86例射血分数降低的心力衰竭(HFrEF)患者的血清Drp1浓度。使用受试者工作特征(ROC)分析评估Drp1的诊断价值。复合终点包括心源性死亡和因HF再次住院,并进一步确定Drp1与临床结局之间的关联。
HFpEF患者的血清Drp1浓度远高于HFrEF患者(4.2±3.7 ng/mL对2.6±2.2 ng/mL,P = 0.001),ROC分析表明其作为区分HF表型的潜在诊断生物标志物,最佳截断点为3.5 ng/mL(曲线下面积(AUC)= 0.659,敏感性:45.9%,特异性:83.7%)。Kaplan-Meier生存分析表明,血清Drp1浓度低(截断值= 2.5 ng/mL,AUC = 0.738)与HF预后不良相关。此外,二元逻辑回归分析确定血清Drp1浓度低是再次住院(比值比(OR)= 6.574,P = 0.001)和复合终点(OR = 5.927,P = 0.001)的独立风险预测因子。
我们的研究结果表明,血清Drp1浓度低可能作为区分HF表型和HF总体预后的预测生物标志物。